Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: Identifying risk factors to help guide treatment selection Journal Article
| Authors: | Bantilan, K. S.; Kay, N. E.; Parikh, S. A.; Rabe, K. G.; Call, T. G.; Leis, J. F.; Ding, W.; Slager, S. L.; Soumerai, J. D.; Roeker, L. E.; Mato, A.; Zelenetz, A. D. |
| Article Title: | Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: Identifying risk factors to help guide treatment selection |
| Abstract: | Targeted therapies have largely replaced chemoimmunotherapy (CIT) in first-line treatment of chronic lymphocytic leukemia (CLL). We aimed to develop a prognostic model to determine who would benefit from first-line CIT vs target therapy. In follicular lymphoma, time from diagnosis to second treatment (TT2T) correlates better with overall survival (OS) than time from diagnosis to first treatment (TT1T). We hypothesized that TT2T is a potential surrogate for OS in CLL. In a model-building cohort (n = 298), we evaluated potential predictors for TT2T and derived a risk score, which we validated in an external cohort (n = 1141). Our data demonstrated that TT2T and OS were more strongly correlated than TT1T and OS. Our risk score model consisted of three predictors (unmutated IGHV, β2-microglobulin >297 nmol/L, and Rai stage I–IV), and was prognostic for TT2T and OS. TT2T is a promising surrogate for OS in CLL, but further validation is needed to establish this association. © 2023 Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | survival; risk factors; pathology; risk factor; targeted therapy; chronic lymphatic leukemia; leukemia, lymphocytic, chronic, b-cell; non-hodgkin lymphoma; chronic lymphocytic leukemia; prognostic model; chemoimmunotherapy; humans; prognosis; human |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 64 |
| Issue: | 2 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2023-01-01 |
| Start Page: | 300 |
| End Page: | 311 |
| Language: | English |
| DOI: | 10.1080/10428194.2022.2148218 |
| PUBMED: | 36503412 |
| PROVIDER: | scopus |
| PMCID: | PMC10629364 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in PubMed and PDF -- Corresponding author is MSK authors: Andrew D. Zelenetz -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work